Experience with new assays for oestrogen receptors using monoclonal antibodies

Autor:	Andrew Krajewski, William A. Ferguson, Pamela A. Levack, Richard A. Hawkins, Sir Patrick Forrest, K. Sangster, Ann L. Tesdale
Rok vydání:	1987
Předmět:	medicine.diagnostic_test medicine.drug_class business.industry medicine.medical_treatment Endocrine therapy Monoclonal antibody Biochemistry Biopsy medicine Cancer research Malignant cells Oestrogen receptor Receptor business Mastectomy
Zdroj:	Biochemical Society Transactions. 15:949-950
ISSN:	1470-8752 0300-5127
Popis:	The oestrogen receptor ( E R ) is a unique oestrogen-binding protein. (M, 66 182) [I]. found in the target cells of oestrogen action. The presence of E R in breast cancers indicates a better prognosis and greater likelihood of response to endocrine therapy [2]. The preparation of monoclonal antibodies against the human ER [3] has lead to the development of new histochemical (ER-ICA) and biochemical (ER-EIA) methods for detecting the protein. We have compared these new assays with our standard radioligand-binding assay [4] (DCC), established 13 years ago, and have related the results for the ER-ICA to response to endocrine therapy. Breast cancers ( I56 in total) were collected from patients undergoing mastectomy or biopsy, and used either fresh or alter storage in liquid nitrogen. For 41 patients, tumour cells were also taken by fine-needle aspiration a t initial presentation; these aspirates were treated with water to lyse erythrocytes and the malignant cells were collected on t o slides by cytocentrifugation according to R. E. Leake, (personal communication) before fixation according to the manufacturer's instructions (Abbott Laboratories Ltd, The Business Centre, Molly Millers Lane, Wokingham. Berkshire). Nine
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6543da1efb15f2d88a5421fd9d2c30da https://doi.org/10.1042/bst0150949 Zobrazit plný text záznamu